Revvity, Inc.
RVTY
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $14.5B
$130.22
▼ -0.31%
P/E
62.01
Mkt Cap
$14.5B
52-Wk Range
$81.22–$133.00
52-Week Range
$81.22 - $133.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 50.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- 86+ year heritage and brand recognition in life sciences and diagnostics with deep customer relationships
- Integrated portfolio combining instruments, reagents, software, and services creating high-margin recurring revenue
- Advanced genomic and next-generation sequencing technologies for oncology, immunodiagnostics, and drug discovery applications
- Global distribution network and regulatory expertise across diagnostics, pharmaceutical, and industrial markets
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Rising demand for genetic screening and early disease detection in diagnostics and personalized medicine
Value
Attractively priced below Life Sciences Tools peer average
Momentum
Hot
+29.8% over 3m
Quality
Strong
Excellent business quality
Dividend
Token
0.22% yield
Smart-money signal
Who's buying RVTY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 26, 2026
AUG 4, 2026
Reported EPS of $1.41 vs $1.21 consensus (+16.5% surprise). Revenue of $711.0M vs $703.0M expected (+1.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+16.5%
Revenue trend · last 8Q
—
+5%
+2%
+4%
+2%
+6%
+7%
+1%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$684.0M
$729.4M
$664.8M
$720.3M
$698.9M
$772.1M
$711.1M
$729.7M
Margins · last 8Q
Gross
57.1%
Operating
12.2%
Profit
7.1%
Wall Street consensus
8 analysts · 38% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
38%
Hold
63%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Sep 1, 2026
vs Industry
How RVTY stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related